Andre Goy, MD
Following in the footsteps of the BTK inhibitor ibrutinib (Imbruvica) in mantle cell lymphoma (MCL), other novel agents are being explored in the relapsed/refractory population.
, Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, Hackensack Medical Center, discussed the excitement surrounding novel therapies on the horizon in MCL.
OncLive: The ZUMA-2 trial is ongoing. What is the potential impact of this study?
ZUMA-2 uses CD19-targeted CAR T cells dedicated for MCL in patients who have failed prior therapy, including ibrutinib. We know that patients who have failed ibrutinib typically have very poor outcomes, and those patients have seen multiple therapies. In this setting, there is no real curative option, expect if a patient can go on allogeneic transplant. The more we give therapies to patients with MCL, the more they become a blastoid-variant [subtype] with a higher prolific disease. They then don’t do well with additional therapies and are very hard to control. Therefore, the ability to [give patients] a CAR T-cell therapy is obviously very appealing.
... to read the full story